Time To Create A Viable Path To Biosimilar Interchangeability
Without a viable path for interchangeability, many companies have been hesitant to pursue biosimilars. The Biologics Price Competition and Innovation Act, therefore, hasn't lived up to its promise of lowering the...To view the full article, register now.
Already a subscriber? Click here to view full article